Clinical Trial Identifier
NCT02128932
Semaglutide injectable (0.5 mg and 1.0 mg), part of the SUSTAIN program.
Trial details
- Identifier
- NCT02128932
- Sponsor
- Novo Nordisk
- Asset
- Semaglutide injectable (0.5 mg and 1.0 mg)
- Program
- SUSTAIN
- Phase
- Phase III
- Therapeutic area
- Type 2 Diabetes
Program context
SUSTAIN
HbA1c reductions of approximately 1.0 to 1.8 percentage points across the program at the 1.0 mg dose; weight reductions of 3 to 6 kg. SUSTAIN-6 demonstrated a 26% relative reduction in the composite MACE endpoint (CV death, non-fatal MI, non-fatal stroke) versus placebo, driven primarily by non-fatal stroke reduction.
Read the SUSTAIN spotlightTrial-level analysis lives in the program spotlight linked above. For the canonical registry record, including study design, eligibility, locations, and posted results, visit ClinicalTrials.gov.